News Headlines

  1. Lupin And Tenpoint Therapeutics Announce Strategic Partnership To Commercialize YUVEZZI In The European Union, The United Kingdom, Switzerland, Norway, And Iceland 8/20/2026

    Global pharma major Lupin Limited ("Lupin") today announced that VISUfarma B.V. ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited ("Tenpoint").

  2. Akiram Therapeutics And ITM Sign Lutetium-177 Supply Agreement To Support Development Of AKIR001 For The Treatment Of Solid Tumors 8/20/2026

    Under the terms of the agreement, ITM will provide its high-quality n.c.a. Lu-177 for use in Akiram's ongoing clinical trial for AKIR001, the company's lead radiopharmaceutical candidate.

  3. Lonza Launches Rapid Custom Media Prototyping Service To Accelerate Early Bioprocess Development 8/20/2026

    Lonza, the world's leading contract development and manufacturing organization (CDMO), today announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. With the possibility to send non-GMP powder batches from 1-10 kg and liquid batches from 1-100 L produced within 10 working days, the service helps scientists accelerate timelines, generate critical process data and prepare for GMP manufacturing.

  4. IDEAYA Biosciences Announces Clinical Collaboration With Genentech In MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer 8/19/2026

    IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) harboring both an MTAP-deletion and a KRAS G12D mutation.

  5. Amplitude Therapeutics And Lilly Enter Strategic Collaboration To Develop Trans-Amplifying RNA Vaccines For Infectious Diseases 8/19/2026

    Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company ("Lilly") to discover and develop taRNA vaccine candidates for infectious diseases.

  6. Piramal Pharma Limited Completes Acquisition Of Controlling Stake In Yapan Bio Private Limited 8/18/2026

    Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL.

  7. Dunbar Pharma Brings First Plant-Derived Dronabinol API To UK Market Through IPS Pharma 8/18/2026

    Dunbar Pharmaceuticals (“Dunbar Pharma” or “the Company”), Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), today announced that its plant-derived dronabinol API, WaterClear THC™, is now available across the United Kingdom.

  8. Chugai And GSK Sign Exclusive License Agreement For Anti-Dengue Virus Antibody AID351 8/18/2026

    Chugai Pharmaceutical Co., Ltd. announced that it has signed an exclusive license agreement with GSK for the anti-dengue virus antibody “AID351” on August 17, 2026. This agreement follows the collaboration agreement for AID351 signed between the two companies on January 30, 2025.

  9. Asimov Announces Cell Line Development Partnership With Kaigene To Advance Multispecific Antibody For Autoimmune Disease 8/18/2026

    Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Kaigene, a biotechnology company pioneering next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases.

  10. Genprex Selects Leading Clinical And Commercial Contract Development And Manufacturing Organization For Manufacturing Scale Up Of Diabetes Gene Therapy 8/18/2026

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program.